Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells are effective treatment for B-cell lymphoma but often cause neurologic toxicity. We treated 20 patients with B-cell lymphoma on a phase I, first-in-humans clinical trial of T cells expressing the novel anti-CD19 CAR Hu19-CD828Z (NCT0265994...

Descripción completa

Detalles Bibliográficos
Autores principales: Brudno, Jennifer N., Lam, Norris, Vanasse, Danielle, Yueh-wei, Shen, Rose, Jeremy J., Rossi, John, Xue, Allen, Bot, Adrian, Scholler, Nathalie, Mikkilineni, Lekha, Roschewski, Mark, Dean, Robert, Cachau, Raul, Youkharibache, Philippe, Patel, Rashmika, Hansen, Brenna, Stroncek, David F., Rosenberg, Steven A., Gress, Ronald E., Kochenderfer, James N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781235/
https://www.ncbi.nlm.nih.gov/pubmed/31959992
http://dx.doi.org/10.1038/s41591-019-0737-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781235/
https://www.ncbi.nlm.nih.gov/pubmed/31959992
http://dx.doi.org/10.1038/s41591-019-0737-3

Ejemplares similares